Strontium Ranelate Promotes Chondrogenesis Through Inhibition of the Wnt/ β -catenin Pathway

Hao Yu

Department of Prosthodontics, Shanghai Stomatological Hospital, Fudan University

Yan Liu

Department of Prosthodontics, Shanghai Stomatological Hospital, Fudan University

Xiangwen Yang

Department of Prosthodontics, Shanghai Stomatological Hospital, Fudan University

Jiajing He

Department of Prosthodontics, Shanghai Stomatological Hospital, Fudan University

Fan Zhang

Department of Orthodontics, Shanghai Stomatological Hospital, Fudan University

Qun Zhong

Department of Prosthodontics, Shanghai Stomatological Hospital, Fudan University

Xiaojing Guo (✉ guo_xiaojing@fudan.edu.cn)

Department of Prosthodontics, Shanghai Stomatological Hospital, Fudan University

<https://orcid.org/0000-0002-6516-0019>

Research Article

Keywords: Strontium ranelate, BMSCs, chondrogenesis, cartilage regeneration, Wnt/ β -catenin pathway

Posted Date: March 23rd, 2021

DOI: <https://doi.org/10.21203/rs.3.rs-346453/v1>

License: This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Abstract

Background

Cartilage regeneration is a key step in functional reconstruction for temporomandibular joint osteoarthritis (TMJ-OA), but is a difficult issue to address. Strontium ranelate (SrR) is an antiosteoporosis drug that has been proven to affect OA in recent years, but its effect on chondrogenesis and the underlying mechanism are still unclear.

Methods

Bone mesenchymal stem cells (BMSCs) from Sprague–Dawley (SD) rats were induced in chondrogenic differentiation medium with or without SrR, XAV-939 and LiCl. CCK-8 assays were used to examine cell proliferation, and alcian blue staining, toluidine blue staining, immunofluorescence and PCR analysis were performed. Western blot (WB) analyses were used to assess chondrogenic differentiation of the cells. For an in vivo study, 30 male SD rats with cartilage defects on both femoral condyles were used. The defect sites were not filled, filled with silica nanosphere plus gelatine-methacryloyl (GelMA) or filled with SrR-loaded silica nanosphere plus GelMA. After 3 months of healing, paraffin sections were made, and toluidine blue staining, safranin O/fast green staining, and immunohistochemical staining were performed for histological evaluation. The data were analysed by SPSS 26.0 software.

Results

Low concentrations of SrR did not inhibit cell proliferation, and the cells treated with SrR (0.25 mmol/L) showed stronger chondrogenesis than the control. XAV-939, an inhibitor of β -catenin, significantly promoted chondrogenesis, and SrR did not suppress this effect, while LiCl, an agonist of β -catenin, strongly suppressed chondrogenesis, and SrR reversed this inhibitory effect. In vivo study showed a significantly better cartilage regeneration by SrR-loaded GelMA than the other treatments.

Conclusion

SrR could promote BMSCs chondrogenic differentiation by inhibiting the Wnt/ β -catenin signalling pathway and accelerate cartilage regeneration in rat femoral condyle defects.

Background

Temporomandibular joint osteoarthritis (TMJ-OA) is a joint degenerative disease characterized by cartilage lesions along with changes in the synovium and degradation of subchondral bone. Epidemiological surveys showed that the prevalence of TMJ-OA was 25% in the 20–49 year age group[1]. The main symptoms of TMJ-OA are joint friction, joint pain, stiffness and functional limitation. Histologically, abnormal synthesis and degradation of articular chondrocytes, extracellular matrix and subchondral bone are detected; as a result, the cartilage becomes thinner and stripped, and subchondral bone is exposed and scleroid[2]. The pathogenesis of TMJ-OA involves inflammation, excessive

mechanical stress, abnormal remodeling of subchondral bone, chondrocyte apoptosis, catabolic disturbances and genetic factors, in which accelerated subchondral bone turnover plays a role in the initiation of TMJ-OA[3]. Subchondral osteosclerosis can lead to dysfunction of the cartilage tissue and cartilage degeneration; conversely, cartilage degeneration can also lead to subchondral bone metabolic disorders, subchondral bone remodeling and sclerosis[4,5]. This vicious cycle strongly promotes the development of OA. Inhibition of this vicious cycle and regeneration of the degraded or even exfoliated cartilage are key to the treatment of OA and the reconstruction of joint function.

For the treatment of TMJ-OA, conventional treatments, including physical therapies, occlusal splints, and anti-inflammatory medications, are often ineffective. Surgical intervention involving joint replacement or cartilage regeneration is important in the clinic[6]. Cartilage regeneration is a key step of functional reconstruction, especially for TMJ-OA, in which the condyle, as the center of mandibular growth and development, is critical in regulating the length and width of the whole mandible. However, cartilage tissue regeneration is also a major challenge, because it is expensive and has limited clinical effects. Due to the poor proliferation of chondroblasts and the lack of blood supply in cartilage tissue, it is difficult for stem cells and chondroblasts to migrate, proliferate and differentiate in defect sites. As research on stem cell therapy has matured, tissue engineering technology with mesenchymal stem cells (MSCs) as seed cells has shown promise for cartilage damage repair[7]. One of the major challenges of stem cell therapy is to control the differentiation of stem cells into chondrocytes. In the past, cytokines were used. Although is highly effective, a great amount of growth factors needs to be applied locally for a long time. The technical requirements and economic cost of obtaining growth factors are high, and long-term release is difficult, which substantially limits the clinical application of this method.

Strontium ranelate (SrR), as an antiosteoporosis drug, can effectively promote bone formation and suppress bone resorption, and its anti-OA effect has been confirmed in recent years. The Strontium Ranelate Efficacy in Knee Osteoarthritis (SEKIOA) phase III clinical trial has provided the most reliable clinical evidence. In this three-year multicenter randomized controlled trial, the SrR-treated patients showed notable pain relief, functional improvement, and radiological amelioration compared with the placebo-treated patients[8,9]. SrR is considered a disease-modifying OA drug (DMOAD) that is used to avoid or delay surgery[10-12]. However, although strong clinical evidence of the anti-OA effect of this drug has been published, the underlying mechanism of SrR is still unclear. Currently, most studies have reported that the anti-OA efficacy of SrR is mediated through the inhibition of subchondral bone resorption via the OPG/RANK/RANKL system[8-13]. It also shows anti-inflammatory effects, especially suppress the expression of matrix metalloproteinases(MMPs). Tat found that SrR could downregulate the mRNA levels of MMP-2 and MMP-9[14], and Pelletier's study showed that SrR downregulated the expression levels of MMP-1, MMP-13 and cathepsin K, thus suppressing bone/cartilage resorption[15]

Strontium ions have a similar molecular structure to Calcium ions and may have similar physiological functions. After SrR acts on the Ca^{2+} ion receptor on the cell membrane surface, it activates the canonical or noncanonical Wnt pathway through the calcineurin-activated T nuclear factor (Cn-NFAT) signalling pathway. Fromigue et al. confirmed that the positive effect of SrR on the Wnt pathway can promote

osteogenic differentiation[16]. However, no studies have examined the effect of SrR on cartilage differentiation, and no experimental evidence in vivo has shown the effect of local SrR administration on cartilage regeneration. Therefore, the main purpose of the present study was to investigate whether SrR has a positive effect on the chondrogenic differentiation of BMSCs and assess the hypothesis that SrR regulates the chondrogenic differentiation of BMSCs through the Wnt/ β -catenin signalling pathway. Then, a cartilage defect model was generated in rat femurs, and a local sustained-release administration method was used to determine whether the local application of SrR can promote cartilage tissue regeneration. The results may provide an alternative for drug application in cartilage tissue engineering.

Methods

Isolation and culture of rat BMSCs

Male SD rats at 4–6 weeks of age were purchased from Vital River Laboratories (Shanghai, China) and sacrificed by an overdose of pentobarbital sodium. After removal all of the soft tissue from the femurs, the marrows were collected from both ends of the femurs and seeded on cell plates to obtain BMSCs. BMSCs at passages 2–4 were used for the present study.

All animal treatments were strictly in accordance with NIH guidelines and were approved by the Animal Research Committee of the Shanghai Stomatological Hospital and Shanghai Research Center of Model Animal Organization (IACUC No. 2020-0010-06).

Treatment with SrR and chondrogenic differentiation medium

51.35 mg *SrR* (Sigma-Aldrich, USA) was dissolved in 50 mL of liquid to obtain the highest concentration of 2.0 mmol/L and diluted to various concentrations as previously described[17].

The chondrogenic differentiation medium was prepared as described by Solchaga[18]. DMEM basic medium (Gibco, 11965175) contained 10 ng/mL TGF- β 3 (Prospec, CYT-886), 100 U penicillin/streptomycin (Gibco, 15140163), 1% foetal bovine serum (Gibco, 10099), 10^{-7} mol/L dexamethasone (Sigma, 50-02-2), 50 mg/L L-ascorbic acid (Sigma, A4403), and 1 $\times$ ITS-A (Gibco, 51300-044) were used.

Cell proliferation assay of BMSCs

CCK-8 assay was used to assess cell proliferation of BMSCs treated with different concentrations of SrR. Briefly, BMSCs were seeded in 96-well plates (starting cell density of 3×10^3 cells/well) and treated with different concentrations of SrR (0.125, 0.25, 0.5, 1.0, and 2.0 mmol/L) for 1, 3, 5, and 7 days. Then, 10 μ L of CCK-8 solution was added to each plate and incubated in the dark in a 5% CO₂ and 37°C environment for 1 h. Cell viability was measured by a microplate reader (ELX 800; Bio-tek Instruments, USA) at a wavelength of 450 nm.

Analysis of the Wnt/ β -catenin signalling pathway

To determine the effect of SrR on the *Wnt/β-catenin* signalling pathway, we used XAV-939 (Selleck, China), an inhibitor of β-catenin, at a concentration of 2.0 μmol/L and LiCl (Sigma, USA), an agonist of β-catenin, at a concentration of 2.0 mmol/L. Grouping was performed as follows: control, 0.25 mmol/L SrR, 0.50 mmol/L SrR, XAV-939, XAV-939 + 0.25 mmol/L SrR, LiCl, and LiCl+ 0.25 mmol/L SrR. After 14 days of induction, alcian blue and toluidine blue staining, immunofluorescence staining, hydroxyproline (Hyp) assays, PCR and Western blot assays were performed.

Alcian blue staining and toluidine blue staining

BMSCs were seeded on 28-well plates at an initial density of 1×10^5 cells/well and changed to chondrogenic differentiation medium with or without SrR, XAV-939, or LiCl. After 14 days of induction, the cells were fixed with 4% paraformaldehyde and stained with Alcian blue dye solution (Solarbio, China) and toluidine blue dye solution (Solarbio, China). Then, the cells were photographed by inverted light microscopy at 200× magnification (Leica DMI 3000B, Germany).

Immunofluorescence staining assay

BMSCs were cultured in chondrogenic differentiation medium with or without SrR, XAV-939 and LiCl for 14 days and fixed with 4% paraformaldehyde for staining. First, the cells were permeabilized with PBST and rinsed with PBS several times. Nonspecific interactions were blocked with goat serum, and the cells were incubated with primary antibodies. Col-II (Novus Biologicals, NB600-844, USA) and MMP-9 (Proteintech, 10375-2, USA) antibodies were used as primary antibodies, Alexa Fluor 488 IgG (Invitrogen, A11001, USA) was used as the secondary antibody, and DAPI (Sigma, D9642) was used for core staining. Cells were photographed by microscopy at 200× magnification.

Hydroxyproline (Hyp) assay

Hyp assay kit (Abcam, ab222941, USA) was used according to the manufacturer's instructions. The cell culture supernatants, ddH₂O and the standard protein sample were prepared, added to an equal volume of NaOH, evaporated, cooled, and neutralized with an equal amount of HCl. Then, the cells were centrifuged, and the supernatants were collected in a new tube. Oxidation reagent was added and incubated at room temperature for 20 minutes, and developer was added and incubated at 37°C for 5 minutes. Then, DMAB concentrate was added and incubated at 65°C for 45 minutes. The OD values of each group were measured at a wavelength of 560 nm. Hyp concentrations were calculated by the standard curve.

Quantitative real-time PCR assay

BMSCs were cultured in 6-well plates and treated with or without SrR, XAV-939, or LiCl for 1, 7, or 14 days. Total RNA was extracted from BMSCs using TRIzol reagent (Ambion, USA), followed by reverse transcription to generate cDNA with Tiangen FastKing cDNA Dispelling RT SuperMix (Applied Biosystems, USA) according to the manufacturer's instructions. For RNA expression analysis, cDNA (100 ng) was

amplified in a 20 μ L reaction system containing 10 μ L of 2 $\times$ SuperReal PreMix Plus, 1.2 μ L of primer and 6.8 μ L of ddH₂O. The primer sequences are listed in Table 1. Triplicate reactions were performed, and the relative fold change in gene expression was calculated (LightCycler 96 PCR **system**, Roche, Germany).

Table 1. Primer sequences used for the BMSCs

Gene target	Primer sequence forward(5'-3')	Primer sequence reverse(5'-3')
Sox-9	TCCCCGCAACAGATCTCCTA	AGCTGTGTGTAGACGGGTTG
Col-II	ATCGCCACGGTCCTACAATG	GGCCCTAATTTTCGGGCATC
MMP-9	GATCCCCAGAGCGTTACTCG	GTTGTGGAAACTCACACGCC
β -catenin	ACTCCAGGAATGAAGGCGTG	GAACTGGTCAGCTCAACCGA
Aggrecan	CAAGTCCCTGACAGACACCC	GTCCACCCCTCCTCACATTG
GAPDH	AGTGCCAGCCTCGTCTCATA	GATGGTGATGGGTTTCCCGT

WB assay

BMSCs were cultured in 6-well plates with chondrogenic differentiation medium with or without SrR, XAV-939, and LiCl for 14 days. Total protein was extracted by RIPA buffer and measured by a BCA protein assay kit. Equal amounts of proteins were subjected to 12% SDS-PAGE and transferred to PCDF membranes. After the membranes were blocked with 5% skim milk, they were exposed to primary antibody, including Sox-9 (Santa Cruz, sc-166505), β -catenin (CST, 9562, USA), MMP-9 (Proteintech, 10375-2), aggrecan (Proteintech, 13880-1), and β -actin antibodies (CST, 4970), at 4°C overnight. Then, the cells were washed with PBST and incubated with HRP-conjugated goat anti-rabbit or rabbit anti-mouse IgG (Beyotime, China) for 2 h at room temperature. The membranes were thoroughly washed, and ECL reagent (Pierce, Rockford, IL, USA) was used for visualization. Bands were photographed and measured by the Quantity One analysis system (Bio-Rad).

Synthesis of SrR-loaded silica nanospheres and GelMA gel

Silica nanospheres were synthesized according to the sol-gel approach as described by a previous study[19]. Briefly, 3.0 g ammonium fluoride (NH₄F) and 1.82 g cetyltrimethylammonium bromide (CTAB) were dissolved in ddH₂O, heated to 80°C and stirred for 1 h. Nine milliliters of tetraethoxysilane (TEOS) was added in a dropwise manner, centrifuged (8000 rpm, 25 minutes) in the suspension solution, and maintained overnight at room temperature. Then, the sample was freeze dried for 12 h, heated to 600°C and calcined for 6 h. For SrR drug loading, the nanospheres were immersed and stirred in PBS containing 2.0 mmol/L SrR for 48 h. The morphology of the silica nanospheres was observed by scanning electron microscopy (SEM) and characterized by energy dispersive spectrum analysis (EDS). Then, the drug releasing speed was tested. We added 80 μ L of SrR at a concentration of 2.0 mmol/L to 0.1 g silica nanospheres, and after it was completely absorbed and dried, these nanospheres were immersed in 2 mL

of PBS at 37°C. In addition, the supernatant was collected and refreshed at 1 h, 2 h, 4 h, 8 h, 12 h, 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, and 9 days. The SrR content was quantified by ultraviolet spectrophotometry.

Product of gelatine methacryloyl, GelMA (ELF, EFL-GM-30, Suzhou, China) were used as scaffold carriers of SrR-loaded nanospheres to obtain desirable mechanical properties. In short, gelatine directly reacts with MA in phosphate buffer, and lithium phenyl-2,4,6-trimethylbenzoylphosphinate (LAP) is used as a photoinitiator[20]. The SrR-loaded nanospheres were mixed with GelMA jelly at a concentration of 0.1 g/mL and incubated in the dark at 4°C for storage.

Animal surgery

Thirty healthy male SD rats at 8–9 weeks of age were purchased from Vital River Laboratories (Shanghai, China) and fed in SPF conditions for 1 week before the surgery. The femoral condyle defect model was established following the procedure of a previous study[21]. Briefly, medial parapatellar arthrotomy was performed on both sides of the knees under general anesthesia, and the femoral trochlea was fully exposed. A round defect with 2.5 mm diameter and 1.0 mm depth was made on the center trochlea by a trephine under cooling with saline. Cartilage defects were left empty for the empty group (n=10) and were filled with GelMA + nanospheres in the control group (n=10). The defects in the test group (n=10) were filled with GelMA + SrR-loaded nanospheres and cured by UV light for 30 s. All of the wounds were carefully sutured, and the muscle layer was reverted back to the original position. The animals were euthanized 3 months after the surgery.

Histological and immunohistochemical evaluation

Samples were collected and fixed in formalin for 3 days, followed by 6 weeks of decalcification. Paraffin sections were made and stained with toluidine blue, safranin O/fast green, MMP-9 (Abcam, ab7003, UK) and β -catenin antibodies (Abcam, ab32572, UK) for immunohistochemical staining.

The histological characteristics of the regenerated cartilage tissue were scored using the International Cartilage Repair Society (ICRS) II scoring system[22], as shown in Table 2. Toluidine blue-stained and safranin O/fast green-stained sections were assessed by three independent doctors blinded to the grouping, and the average scores were calculated.

Table 2. The International Cartilage Repair Society II scoring system[22]

Histological parameter	Score (0–100)
1. Tissue morphology	0: Full thickness collagen fibers 100: Normal cartilage birefringence
2. Matrix staining	0: No staining 100: Full metachromasia
3. Cell morphology	0: No round/oval cells 100: Mostly round/oval cells
4. Chondrocyte clustering	0: Present 100: Absent
5. Surface architecture	0: Delamination or major irregularity 100: Smooth surface
6. Basal integration	0: No integration 100: Complete integration
7. Formation of a tidemark	0: No calcification front 100: Tidemark
8. Subchondral bone abnormalities/marrow fibrosis	0: Abnormal 100: Normal marrow
9. Inflammation	0: Present 100: Absent
10. Abnormal calcification/ossification	0: Present 100: Absent
11. Vascularization (within the repaired tissue)	0: Present 100: Absent
12. Surface/superficial assessment	0: Total loss or complete disruption 100: Resembles intact articular cartilage
13. Mid/deep zone assessment	0: Fibrous tissue 100: Normal hyaline cartilage
14. Overall assessment	0: Bad, fibrous tissue 100: Good, hyaline cartilage

Statistical analysis

Data are shown as the mean $\pm$ SD and were analysed by SPSS 26.0 software. One-way analysis of variance (ANOVA) was used to determine the statistical significance of the differences among groups, and a P value < 0.05 was considered statistically significant.

Results

Cell proliferation assay of BMSCs

CCK-8 assays showed a clear dose-dependent effect of SrR on cell proliferation, and high concentrations (0.5, 1.0, and 2.0 mmol/L) of SrR significantly suppressed cell viability at days 3, 5, and 7 (P < 0.05). However, low concentrations (0.125, 0.25, and 0.5 mmol/L) of SrR did not influence the proliferation of BMSCs at days 1, 3, 5, and 7, and no significant differences were observed between the control group and the 0.125 and 0.25 mmol/L groups (Figure 2).

Alcian blue staining and toluidine blue staining

Alcian blue staining showed the distribution and content of glycosaminoglycans (GAGs) produced by cells[23], and toluidine blue staining indicated the content of proteoglycans (PGs)[24]. Darker staining indicates better cell chondrogenesis. As shown in Figure 3, a low concentration of SrR (0.25 mmol/L) resulted in darker staining than that in the control group and the high concentration group (0.50 mmol/L). LiCl treatment significantly suppressed chondrogenic differentiation; in this group, cells shrank or did not show any phenotypic changes and showed weak staining. LiCl plus SrR could improve the chondrogenic differentiation, resulting in darker staining than that in the LiCl group. XAV-939 is an inhibitor of β -catenin but shows a strong chondrogenic effect. We found the darkest staining in the XAV-939 and XAV-939+SrR groups, with no major differences within the groups.

Hyp assay

Hyp is a characteristic amino acid and a degradation product of collagen. A high content of Hyp in the matrix indicates collagen degradation. We found a significantly lower content of Hyp in the 0.25 mmol/L SrR group than in the control group and an increasing trend of Hyp with higher concentrations of SrR. XAV939 substantially suppressed the secretion of Hyp, while XAV-939 + SrR resulted in a slight but not significant increase in Hyp content. The LiCl groups had the opposite results: these groups had the highest content of Hyp, and SrR treatment suppressed this effect, without significant differences.

Wnt/ β -catenin signalling pathway analysis

We first tested the effect of β -catenin inhibitors/agonists at the gene level. PCR assays revealed that inhibition of β -catenin expression (XAV-939) increased the expression of Sox-9 and aggrecan, chondrogenic biomarkers, by 13.05-fold and 7.62-fold, respectively, on day 14 compared with that on the first day. Induction of β -catenin (LiCl) decreased the expression of Sox-9 and aggrecan to 0.44-fold and

1.01-fold on day 1 and 1.27-fold and 1.50-fold on day 14, respectively; these values were much lower than those of the control group at each time point ($P < 0.05$). The XAV-939 and XAV-939 + SrR groups did not show any significant differences within the groups. LiCl + SrR treatment significantly increased the expression of Sox-9 and aggrecan compared with that in the LiCl group. MMP-9 is negatively associated with these genes and causes matrix degradation. We observed the opposite trend for MMP-9 expression compared to Sox-9 and aggrecan expression. SrR significantly suppressed β -catenin expression with LiCl treatment, but the expression of this molecule was not upregulated in the XAV-939 groups (Figure 5A). Then, we performed protein assays. Immunofluorescence staining of the Col-II protein showed that the cells did not display any phenotypic changes after 14 days of induction with the β -catenin agonist LiCl, and LiCl plus SrR resulted in a stronger fluorescence intensity, which may indicate improved chondrogenic differentiation (Figure 5B). WB assays also revealed that the protein expression showed a similar trend as the gene expression (Figure 5C and 5D): SrR suppressed β -catenin expression, thus increasing the protein expression of Sox-9 but not aggrecan.

* $P < 0.05$ versus the control. Figure 5B presents the results of immunofluorescence staining of the Col-II protein. Figure 5C and 5D show the results of WB assays. Sox-9 and aggrecan showed significantly higher expression and MMP-9 and β -catenin showed significantly lower expression in the SrR treatment group than in the control group. XAV-939 significantly stimulated the synthesis of Sox-9 and aggrecan, inhibited MMP-9 and β -catenin expression, and induced a similar trend when SrR was added. LiCl had the opposite effect: it downregulated Sox-9 and aggrecan expression and upregulated MMP-9 and β -catenin expression, and SrR could also reverse these effects. The results were similar at both the gene and protein levels.

SrR-loaded silica nanospheres and GelMA gel

The average size of the silica nanospheres was 100 ± 20 nm, with an inconspicuous hollow structure on the surface (Figure 6B and C). The EDS analysis showed 53.26% O and 46.74% Si, similar to that of pure silica ingredients (Figure 6D). The drug release test revealed an initial burst release of SrR on the first day and a sustained controlled release until complete release on day 7 (Figure 6E). We mixed SrR-loaded silica nanospheres with UV-cured GelMA gel (Figure 6A), and the degradation of the GelMA was very slow. It required 40 days for complete absorption under the skin in nude mice[25], and we failed to observe any dissolution of GelMA in PBS liquid with changing the PBS every day for 14 days. Therefore, we believed that the burst release of SrR from silica nanospheres did not matter, that the long-term controlled releasing of SrR in cartilage tissue could be achieved by the GelMA gel.

Histological observation

After 12 weeks of healing, we sacrificed all of the rats and observed obvious tissue repair in the SrR treatment group compared with the empty group and the control group by the naked eye (Figure 7A-C). Figure 7A, D and G show the empty group in which the wound was not filled; Figure 7B, E and H show the control group with silica nanospheres plus GelMA gel; and Figure 7C, F and I show the SrR group with SrR-loaded silica nanospheres plus GelMA gel. Toluidine blue staining (Figure 7D, E and G) and safranin

O/fast green staining (Figure 7G, H and I) revealed that the SrR group had a better cartilage repair effect and significantly higher ICRS-II scores than the other two groups (Figure 7J). The cartilage defect with a diameter of 2.5 mm could not be self-healed, as shown by the empty group in which the fibrous tissues had many vessels inside but no hyaline cartilage. GelMA gel with silica nanospheres could significantly induce cartilage regeneration. Basal integration and a smooth surface with different levels of chondrification could be found in the control group and the SrR group, but the SrR group had a better performance than the control group. And there were more subchondral bone abnormalities or abnormal calcification around the defect area in empty group.

Immunohistochemical analysis

Immunohistochemistry (IHC) staining showed the localization of β -catenin and MMP-9 during cartilage regeneration. β -catenin accumulated in fibrous tissue and in blood vessels, chondrocytes were darkly stained, and the basal line of the cartilage layer may be the frontier of chondrification (Figure 8B, E and H), while mature cartilage was not stained. MMP-9 was stained in the inflammatory area, and the normal cartilage area was not stained (Figure 8C, F and I).

Discussion

SrR not only inhibited subchondral bone resorption but also directly promoted chondrogenic differentiation of stem cells. Our results showed that SrR significantly promoted the contents of GAGs and PGs and increased the expression of cartilage marker genes and proteins such as Sox-9, Col-II, and aggrecan in chondrogenic differentiation medium. These results verified the conclusions of previous studies. As early as 1985, Reinholt found that Sr ions could stimulate cartilage regeneration and enhance the aggregation of PGs and hyaluronic acid, thus inducing chondrocytes to produce extracellular matrix in the epiphyseal area[26]. Henrotin treated chondrocytes from OA patients with SrR and found that SrR could strongly stimulate PG synthesis, promote the activity of insulin-like growth factor-1 (IGF-I), and effectively inhibit the expression of MMPs[27]. Yu found that SrR could also increase the synthesis of type II collagen and PGs by upregulating the expression of Sox-9, a biomarker of chondrogenic differentiation[28]. These results all confirmed the role of SrR in promoting chondrogenesis at the cellular level.

Chondrogenic differentiation of stem cells is a complex procedure. The Wnt signalling pathway plays an important role in cell proliferation, migration and also the chondrogenic differentiation. The mechanism of the Wnt pathway in chondrogenic differentiation is complicated, involves many bidirectionally regulated factors and varies at different times[29,30]. Among these pathways, the canonical Wnt pathway has been relatively well studied. β -catenin is the key controlling element of the canonical Wnt pathway. The signalling pathway triggers frizzled protein (FZD) and low-density lipoprotein receptor-related protein 5/6 (LRP5/6) to phosphorylate disheveled protein (DVL) to inhibit glycogen synthase kinase-3 β (GSK-3 β). The inhibition of GSK-3 β induces β -catenin disassociation from adenomatosis polyposis coli (APC), Axin and GSK-3 β . Then, unphosphorylated β -catenin accumulates in the cytoplasm and transfers to the

nucleus, where it acts as a coactivator of the Tcf/Lef transcription factor to regulate the transcription of downstream genes[31-33]. The canonical Wnt/ β -catenin pathway has a negative regulatory effect on chondrogenesis. Many studies have confirmed that β -catenin can inhibit Sox-9 expression while promoting RunX-2 expression. When the Wnt/ β -catenin pathway is activated, stem cells show a trend of osteogenic differentiation, while inhibition of the Wnt/ β -catenin pathway will lead to chondrogenic differentiation, even if cells are cultured in osteogenic induction medium[34-37]. Negative functional interactions between β -catenin and Sox-9 were reported by Akiyama H, and the inhibitory effect between β -catenin and Sox-9 was reciprocal. On the one hand, β -catenin binds to the Sox-9 transactivation domain and induces Sox-9 degradation; on the other hand, Sox-9 represses β -catenin/Tcf/Lef complex activities. There are β -catenin binding sites on the surface of Sox-9 protein, and its sequence is similar of that on Tcf/Lef, thus the formation of the Sox-9/ β -catenin complex could competitively inhibit the binding of Tcf/Lef and β -catenin. Sox-9/ β -catenin complex leads to the degradation of β -catenin through the ubiquitination/26S proteasome pathway[38]. In present study, XAV-939, which targets the tankyrase enzyme, was used as an antagonist of β -catenin[39], and the results showed a significant promotion of chondrogenic differentiation. LiCl promotes the accumulation of β -catenin by inhibiting GSK-3 β , which was used as an agonist of β -catenin[40], and inhibition of chondrogenic differentiation was observed. These results confirmed the negative regulatory effect of the Wnt/ β -catenin pathway on chondrogenic differentiation. There were also suggestions indicated that the Wnt/ β -catenin pathway was suppressed only in the early stage of stem cell chondrogenic differentiation (within 21 days) and was not inhibited beyond this period[41]. This phenomenon was not observed in our study because we only did 14 days of induction.

Our study revealed the role of SrR in promoting chondrogenic differentiation by inhibiting β -catenin. We found that adding a low concentration (0.25 mmol/L) of SrR to the chondrogenic induction solution could inhibit the expression of β -catenin and increase the expression of Sox-9, Col-II, aggrecan and other chondrogenic biomarker proteins. β -catenin agonists significantly inhibited chondrogenic differentiation of BMSCs, while SrR relieved this inhibition. Inhibition of β -catenin significantly promoted chondrogenic differentiation, while SrR addition did not further enhance this effect but also did not suppress it. These results suggested that SrR promoted the chondrogenic differentiation of stem cells by inhibiting β -catenin. Theoretically, Sr has a similar molecular structure and physiological function as calcium. As described before, SrR could activate the Ca²⁺ receptor on the cell membrane surface, enhance the expression of Wnt3a through the Cn-NFAT pathway, and then activate the canonical Wnt/ β -catenin pathway. SrR can also increase the expression of Wnt5a, the FZD receptor family and Ror2/Ryk coreceptors and regulate the downstream RhoA-, JNK- and Ca²⁺-dependent signalling pathways through the noncanonical Wnt pathway to promote the proliferation and differentiation of osteoblast cells[16]. Our results showed that SrR could inhibit β -catenin, thus the canonical Wnt pathway in chondrogenic induction environment. But, whether SrR acts directly on β -catenin or through the Cn-NFAT pathway still needs further investigation.

The results of the in vivo study confirmed that the local release of SrR has a superior effect in promoting cartilage regeneration. As shown by toluidine blue and safranin O/fast green staining, in the empty group without any scaffold, their cartilage defect areas were filled with fibrous tissue, and no cartilage regeneration could be observed. This finding indicates that the round cartilage defect with a diameter of 2.5 mm could not be self-healed in rats. While, notable cartilage regeneration was observed with GelMA filling, and a much better regenerative effect was observed in the SrR-loaded GelMA group, which had higher ICRS-II scores than other groups. IHC staining revealed the expression of β -catenin in the frontier of chondrification. β -catenin was intensely stained in prehypertrophic chondrocytes and periosteal cells and in blood cells but showed weaker or no staining in mature cartilage tissue. MMP-9 is an inflammatory factor that accumulates in fibrous tissue. Weaker β -catenin and MMP-9 staining was observed in the area with better cartilage regeneration. The application of drugs has been a prospective treatment option for cartilage tissue engineering in OA. Drugs, as pure chemicals, show no immunogenicity, are relatively safe, are easily obtained, and can be easily stored and used[42]. Our results showed that SrR could be used as a drug for cartilage tissue engineering and has a good effect on cartilage regeneration.

Conclusions

SrR could promote BMSC chondrogenic differentiation by inhibiting the Wnt/ β -catenin signalling pathway and accelerate cartilage regeneration in rat femoral condyle defects. SrR could be an alternative drug option for cartilage tissue engineering.

Abbreviations

APC: adenomatosis polyposis coli

BMSCs: Bone mesenchymal stem cells

Cn-NFAT: calcineurin-activated T nuclear factor

CTAB: cetyltrimethylammonium bromide

DMOAD: disease-modifying osteoarthritis drug

DVL: disheveled protein

EDS: energy dispersive spectrum

FZD: frizzled protein

GAGs: glycosaminoglycans

GelMA: gelatine methacryloyl

GSK-3 β : glycogen synthase kinase-3 β

Hyp: hydroxyproline

ICRS-II: International Cartilage Repair Society - II scoring system

IGF-I: insulin-like growth factor-1

LAP: lithium phenyl-2,4,6-trimethylbenzoylphosphinate

LRP5/6: low-density lipoprotein receptor-related protein 5/6

MMPs: matrix metalloproteinases

PGs: proteoglycans

SD rat: Sprague–Dawley rat

SEKIOA: Strontium Ranelate Efficacy in Knee Osteoarthritis

SEM: scanning electron microscopy

SrR: strontium ranelate

TEOS: tetraethoxysilane

TMJ-OA: temporomandibular joint osteoarthritis

Declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Availability of data and materials

All data generated or analysed during this study are included in this published article.

Competing interests

The authors have declared that no competing interests exist.

Funding

The authors acknowledge the financial support from the Shanghai Commission of Science and Technology (19YF1442400).

Authors' contributions

Hao Yu and Yan Liu are co-first authors who did most of the cell molecular biological tests and the animal surgery, they contributed equally to this study. Xiangwen Yang did the statistical analysis. Jiajing He made the paraffin sections of animal samples and took the photographs. Fan Zhang helped with the cell culture and some parts of the molecular biological tests. Qun Zhong was responsible for study design and revised the manuscript. Xiaojing Guo as the corresponding author did the study design, statistical analysis and wrote the paper.

Acknowledgements

The authors thank the core facilities of Shanghai Key Laboratory of Craniomaxillofacial Development and Diseases, Fudan University, and Shanghai Research Centre of Model Organisms (SRCMO) for assistances and executing all of the experiments. Authors also acknowledge the financial supports from the Shanghai Commission of Science and Technology (19YF1442400).

References

1. Bernhardt O , Biffar R , Kocher T , et al. Prevalence and clinical signs of degenerative temporomandibular joint changes validated by magnetic resonance imaging in a non-patient group[J]. *Annals of Anatomy-anatomischer Anzeiger*, 2007, 189(4):342-346.
2. Shoukri B , Prieto J C , Ruellas A , et al. Minimally Invasive Approach for Diagnosing TMJ Osteoarthritis[J]. *Journal of Dental Research*, 2019, 98(10):1103-1111.
3. Wang X D , Zhang J N , Gan Y H , et al. Current understanding of pathogenesis and treatment of TMJ osteoarthritis[J]. *Journal of Dental Research*, 2015, 94(5):666.
4. Bijlisma JW , Berenbaum F , Lafeber FP . Osteoarthritis: an update with relevance for clinical practice[J]. *Lancet*. 2011; 377(9783): 2115– 26.
5. Alexandersen P , Karsdal MA , Qvist P , Reginster JY , Christiansen C . Strontium ranelate reduces the urinary level of cartilage degradation biomarker CTX-II in postmenopausal women[J]. *Bone*. 2007 ; 40(1) :218 – 22 .
6. Roseti L , Desando G , Cavallo C , et al. Articular Cartilage Regeneration in Osteoarthritis[J]. *Cells*, 2019, 8(11):1305-.
7. Zhang S, Yap A U J, Wei S T. Stem Cells for Temporomandibular Joint Repair and Regeneration[J]. *Stem Cell Reviews & Reports*, 2015, 11(5):728-742.
8. Reginster J Y, Badurski J, Bellamy N, et al. Extended report: Efficacy and safety of strontium ranelate in the treatment of knee osteoarthritis: results of a double-blind, randomised placebo-controlled trial[J]. *Annals of the Rheumatic Diseases*, 2013, 72(6):e13.

9. Han W , Fan S , Bai X , et al. Strontium ranelate, a promising disease modifying osteoarthritis drug[J]. Expert Opinion on Investigational Drugs, 2017, 26(3):375-380.
10. Jean-Pierre, Pelletier, Camille, et al. Disease-modifying effect of strontium ranelate in a subset of patients from the Phase III knee osteoarthritis study SEKOIA using quantitative MRI: reduction in bone marrow lesions protects against cartilage loss[J]. Annals of the Rheumatic Diseases, 2015, 74(2):422-429.
11. Tenti S , Cheleschi S , Guidelli G M , et al. What about strontium ranelate in osteoarthritis? Doubts and securities.[J]. Modern Rheumatology, 2014, 24(6):881-884.
12. Rodrigues T A , Freire A O , Bonfim B F , et al. Strontium ranelate as a possible disease-modifying osteoarthritis drug: a systematic review[J]. Braz J Med Biol Res, 2018, 51(8).
13. Marie PJ , Felsenberg D , Brandi ML . How strontium ranelate, via opposite effects on bone resorption and formation, prevents osteoporosis[J] . Osteoporos Int. 2011 ; 22(6) : 1659 – 67.
14. Tat SK, Pelletier JP, Mineau F, Caron J, Martel-Pelletier J . Strontium ranelate inhibits key factors affecting bone remodeling in human osteoarthritic subchondral bone osteoblasts [J]. Bone. 2011; 49(3) :559 – 67 .
15. Pelletier J P, Kapoor M , Fahmi H , Lejeune D , Balesius A , Maillet J, Martel-Pelletier J . Strontium ranelate reduces the progression of experimental dog osteoarthritis by inhibiting the expression of key proteases in cartilage and of IL-1 β in the synovium[J]. Ann Rheum Dis. 2013 ; 72(2) : 250 – 7 .
16. Fromiguet O , Hay E , Barbara A , et al. Essential Role of Nuclear Factor of Activated T Cells (NFAT)-mediated Wnt Signalling in Osteoblast Differentiation Induced by Strontium Ranelate[J]. Journal of Biological Chemistry, 2010, 285(33):25251.
17. Xiaojing Guo, Silong Wei, Mengmeng Lu, Zhengwei Shao, Jiayu Lu, Lunguo Xia, Kaili Lin, Derong Zou. Dose-dependent Effects of Strontium Ranelate on Ovariectomy Rat Bone Marrow Mesenchymal Stem Cells and Human Umbilical Vein Endothelial Cells[J]. International journal of Biological Sciences, 2016, 12(12): 1511-1522.
18. Solchaga L A , Penick K J , Welter J F . Chondrogenic Differentiation of Bone Marrow-Derived Mesenchymal Stem Cells: Tips and Tricks[J]. Methods in Molecular Biology, 2011, 698:253.
19. Zhang Y , Chang M , Bao F , et al. Multifunctional Zn doped hollow mesoporous silica/polycaprolactone electrospun membranes with enhanced hair follicle regeneration and antibacterial activity for wound healing[J]. Nanoscale, 2019, 11 (13) , 6315-6333.
20. Yue K , Santiago T D , Alvarez M M , et al. Synthesis, properties, and biomedical applications of gelatin methacryloyl (GelMA) hydrogels[J]. Biomaterials, 2015;73, 254–271.
21. Takahashi I , Hosono M , Matsuzaki T . Histopathological Effects of Loading on Cartilage Repair in a Rat Full-thickness Articular Cartilage Defect Model[J]. Journal of Physical Therapy Science, 2012, 24(11):1187-1190.
22. Mainil-Varlet P , Van Damme B , Nesic D , et al. A new histology scoring system for the assessment of the quality of human cartilage repair: ICRS II.[J]. American Journal of Sports Medicine, 2010, 38(5):880.

23. Irani S , Honarpardaz A , Choubini N , et al. Chondro-inductive nanofibrous scaffold based gelatin/polyvinylalcohol/chondroitin sulfate for cartilage tissue engineering[J]. *Polymers for Advanced Technologies*, 2020, 31(6).
24. Bergholt NL, Lysdahl H, Lind M, Foldager CB. A Standardized Method of Applying Toluidine Blue Metachromatic Staining for Assessment of Chondrogenesis[J]. *CARTILAGE*. 2019;10(3):370-374.
25. Wang Z , An G , Zhu Y , et al. 3D-printable self-healing and mechanically reinforced hydrogels with host–guest non-covalent interactions integrated into covalently linked networks[J]. *Materials Horizons*, 2019.
26. Reinholt FP , Engfeldt B , Heinegard D , Hjerpe A . Proteoglycans and glycosaminoglycans of normal and strontium rachitic epiphyseal cartilage[J] . *Coll Relat Res*. 1985; 5(1) : 41 – 53 .
27. Henrotin Y, L abasse A , Z heng SX, G alais P, T souderos Y, Crielaard JM, et al . Strontium ranelate increases cartilage matrix formation[J]. *Bone Miner Res*. 2001;16(2): 299 – 308 .
28. Yu D G , Ding H F , Mao Y Q , et al. Strontium ranelate reduces cartilage degeneration and subchondral bone remodeling in rat osteoarthritis model[J]. *Acta Pharmacologica Sinica*, 2013, 34(3).
29. Monteagudo, S., Lories, R. Cushioning the cartilage: a canonical Wnt restricting matter[J]. *Nat Rev Rheumatol* 2017,13, 670–681.
30. Lories R J , Corr M , Lane N E . To Wnt or not to Wnt: the bone and joint health dilemma[J]. *Nature Reviews Rheumatology*, 2013, 9(6):328.
31. Clevers Wnt/beta-catenin signalling in development and disease[J]. *Cell* 2006; 127(3): 469-80.
32. Clevers H, Nusse R. Wnt/beta-catenin signalling and disease[J]. *Cell* 2012; 149(6): 1192-205.
33. Nusse R , Clevers H . Wnt/ β -Catenin Signalling, Disease, and Emerging Therapeutic Modalities[J]. *Cell*, 2017, 169(6):985-999.
34. Fang M , Alfieri C M , Hulin A , et al. Loss of β -Catenin Promotes Chondrogenic Differentiation of Aortic Valve Interstitial CellsSignificance[J]. *Arteriosclerosis Thrombosis & Vascular Biology*, 2014, 34(12):2601-8.
35. Timothy, F, Day, et al. Wnt/ β -Catenin Signalling in Mesenchymal Progenitors Controls Osteoblast and Chondrocyte Differentiation during Vertebrate Skeletogenesis[J]. *Developmental Cell*, 2005, 8(5):739-750.
36. Theo P. Hill, Daniela Später, Makoto M. Taketo, Walter Birchmeier, Christine Hartmann, Canonical Wnt/ β -Catenin Signalling Prevents Osteoblasts from Differentiating into Chondrocytes[J]. *Developmental Cell*, 2005, 8(5):727-738.
37. Luo S , Shi Q , Zha Z , et al. Inactivation of Wnt/ β -catenin signalling in human adipose-derived stem cells is necessary for chondrogenic differentiation and maintenance.[J]. *Biomedicine and Pharmacotherapy*, 2013, 67(8):819-824.
38. Akiyama, H. Interactions between Sox9 and beta-catenin control chondrocyte differentiation.[J]. *Genes Dev*, 2004, 18(9):1072-1087.

39. Huang S M A , Mishina Y M , Liu S , et al. Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling.[J]. Nature, 2009, 461(7264):614-620.
40. Philippe Clément-Lacroix, Ai M , Morvan F , et al. Lrp5-independent activation of Wnt signalling by lithium chloride increases bone formation and bone mass in mice[J]. Proceedings of the National Academy of Sciences, 2005, 102(48):17406-17411.
41. Im G I , Quan Z . The effects of Wnt inhibitors on the chondrogenesis of human mesenchymal stem cells.[J]. Tissue Engineering Part A, 2010, 16(7):2405.
42. Roseti L , Desando G , Cavallo C , et al. Articular Cartilage Regeneration in Osteoarthritis[J]. Cells, 2019, 8(11):1305-1321.

Figures

Figure 1

Animal surgical procedures. A cylindrical defect 2.5 mm in width and 1.0 mm in depth was made on the centre of the trochlea and filled with UV-cured GelMA gelatine with or without SrR-loaded nanospheres.

CCK-8

Figure 2

CCK-8 assays of the BMSCs treated with different concentrations of SrR.

Figure 3

Toluidine blue staining (A) and alcian blue staining (B) of BMSCs under chondrogenic differentiation with 0.25 mmol/L SrR and with or without LiCl or XAV-939 (magnification 200×). The result showed darker staining in the 0.25 mmol/L SrR group than the control and 0.50 mmol/L groups. The LiCl groups showed significantly weaker staining, while the LiCl plus SrR group showed darker staining. The XAV-939 and XAV-939 + SrR groups showed the darkest staining.

Figure 4

The result of Hyp assays. A significant decrease in Hyp content was detected in the 0.25 mmol/L SrR group on days 7 and 14. The XAV-939 groups had the lowest secretion of Hyp, and SrR could slightly increase the Hyp content. In contrast, the LiCl groups showed the highest secretion of Hyp, and SrR could slightly suppress the Hyp content. *P<0.05 versus the control.

Figure 5

The results of Wnt/ β -catenin signalling pathway analysis. Figure 5A shows the PCR assays of Sox-9 (1), MMP-9 (2), aggrecan (3), and β -catenin (4). Data are presented as the mean $\pm$ SD. *P<0.05 versus the control. Figure 5B presents the results of immunofluorescence staining of the Col-II protein. Figure 5C and 5D show the results of WB assays. Sox-9 and aggrecan showed significantly higher expression and MMP-9 and β -catenin showed significantly lower expression in the SrR treatment group than in the

control group. XAV-939 significantly stimulated the synthesis of Sox-9 and aggrecan, inhibited MMP-9 and β -catenin expression, and induced a similar trend when SrR was added. LiCl had the opposite effect: it downregulated Sox-9 and aggrecan expression and upregulated MMP-9 and β -catenin expression, and SrR could also reverse these effects. The results were similar at both the gene and protein levels.

Figure 6

The GelMA gel and silica nanospheres. Gelatinous GelMA could be solidified by UV light (Figure 6A). The silica nanospheres under SEM observation (Figure 6B and 6C) and EDS analysis showed their pure silica content (Figure 6D) and the controlled release of SrR for up to 7 days (Figure 6E).

Figure 7

Histological observation. Figure 7A, D and G show the empty group in which the wound was not filled; Figure 7B, E and H show the control group in which the wound was filled with silica nanospheres plus GelMA gel; and Figure 7C, F and I show the SrR group in which the wound was filled with SrR-loaded silica nanospheres plus GelMA gel. Toluidine blue staining (Figure 7D, E and G) and safranin O/fast green staining (Figure 7G, H and I) revealed that the SrR group had a better cartilage tissue repair effect and significantly higher ICRS-II scores than the other two groups (Figure 7J).

Figure 8

Safranin O/fast green staining (Figure 8A, D and G) and IHC staining of β -catenin (Figure 8B, E and H) and MMP-9 (Figure 8C, F and I) were performed. The arrows show the staining of β -catenin in fibrous tissue, chondrocytes, and the frontier of chondrification and MMP-9 in the inflammatory area (magnification 50 $\times$).